An Analysis Regarding the Association Between Proteasome (PSM) and Hepatocellular Carcinoma (HCC)

References

• Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet. 2018;391(10127):1301–1314. doi:10.1016/S0140-6736(18)30010-2
   PubMed Web of Science ®Google Scholar
• Llovet JM, Kelley RK, Villanueva Aet al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2021;7(1):7. doi:10.1038/s41572-021-00245-6
   PubMed Web of Science ®Google Scholar
• Llovet JM, Pinyol R, Kelley RK, et al. Molecular pathogenesis and systemic therapies for hepatocellular carcinoma. Nat Cancer. 2022;3(4):386–401. doi:10.1038/s43018-022-00357-2
   PubMedGoogle Scholar
• Sim HW, Knox J. Hepatocellular carcinoma in the era of immunotherapy. Curr Probl Cancer. 2018;42(1):40–48. doi:10.1016/j.currproblcancer.2017.10.007
   PubMed Web of Science ®Google Scholar
• Johnston MP, Khakoo SI. Immunotherapy for hepatocellular carcinoma: current and future. World J Gastroenterol. 2019;25(24):2977–2989. doi:10.3748/wjg.v25.i24.2977
   PubMed Web of Science ®Google Scholar
• Anwanwan D, Singh SK, Singh S, et al. Challenges in liver cancer and possible treatment approaches. Biochim Biophys Acta Rev Cancer. 2020;1873(1):188314. doi:10.1016/j.bbcan.2019.188314
   PubMed Web of Science ®Google Scholar
• Liu CY, Chen KF, Chen PJ. Treatment of Liver Cancer. Cold Spring Harb Perspect Med. 2015;5(9):a021535. doi:10.1101/cshperspect.a021535
   PubMed Web of Science ®Google Scholar
• Rajendran L, Ivanics T, Claasen MP, et al. The management of post-transplantation recurrence of hepatocellular carcinoma. Clin Mol Hepatol. 2022;28(1):1–16. doi:10.3350/cmh.2021.0217
   PubMed Web of Science ®Google Scholar
• Santhakumar C, Gane EJ, Liu K, et al. Current perspectives on the tumor microenvironment in hepatocellular carcinoma. Hepatol Int. 2020;14(6):947–957. doi:10.1007/s12072-020-10104-3
   PubMed Web of Science ®Google Scholar
• Chute CG. Clinical classification and terminology: some history and current observations. J Am Med Inform Assoc. 2000;7(3):298–303. doi:10.1136/jamia.2000.0070298
   PubMed Web of Science ®Google Scholar
• Berlth F, Bollschweiler E, Drebber U, et al. Pathohistological classification systems in gastric cancer: diagnostic relevance and prognostic value. World J Gastroenterol. 2014;20(19):5679–5684. doi:10.3748/wjg.v20.i19.5679
   PubMed Web of Science ®Google Scholar
• Wang L, Su M, Zhang M, et al. Accurate Prediction of Prognosis by Integrating Clinical and Molecular Characteristics in Colon Cancer. Front Cell Dev Biol. 2021;9:664415. doi:10.3389/fcell.2021.664415
   PubMed Web of Science ®Google Scholar
• Chen S, Li Y, Qian L, et al. A Review of the Clinical Characteristics and Novel Molecular Subtypes of Endometrioid Ovarian Cancer. Front Oncol. 2021;11:668151. doi:10.3389/fonc.2021.668151
   PubMed Web of Science ®Google Scholar
• Wang K, He H, Feng X. Construction of Metabolic Molecular Classification and Immune Characteristics for the Prognosis Prediction of Ovarian Cancer. J Immunol Res. 2022;2022:2359349. doi:10.1155/2022/2359349
   PubMed Web of Science ®Google Scholar
• Long S, Chen Y, Wang Y, et al. Identification of Ferroptosis-related molecular model and immune subtypes of hepatocellular carcinoma for individual therapy. Cancer Med. 2023;12(2):2134–2147. doi:10.1002/cam4.5032
   PubMed Web of Science ®Google Scholar
• Haselkorn R, Rothman-Denes LB. Protein synthesis. Annu Rev Biochem. 1973;42(1):397–438. doi:10.1146/annurev.bi.42.070173.002145
   PubMedGoogle Scholar
• Bard JAM, Goodall EA, Greene ER, et al. Structure and Function of the 26S Proteasome. Annu Rev Biochem. 2018;87:697–724. doi:10.1146/annurev-biochem-062917-011931
   PubMed Web of Science ®Google Scholar
• Çetin G, Klafack S, Studencka-Turski M, et al. The Ubiquitin-Proteasome System in Immune Cells. Biomolecules. 2021;11(1):60. doi:10.3390/biom11010060
   PubMed Web of Science ®Google Scholar
• Park J, Cho J, Song EJ. Ubiquitin-proteasome system (UPS) as a target for anticancer treatment. Arch Pharm Res. 2020;43(11):1144–1161. doi:10.1007/s12272-020-01281-8
   PubMed Web of Science ®Google Scholar
• Devoy A, Soane T, Welchman R, et al. The ubiquitin-proteasome system and cancer. Essays Biochem. 2005;41:187–203. doi:10.1042/bse0410187
   PubMed Web of Science ®Google Scholar
• Aliabadi F, Sohrabi B, Mostafavi E, et al. Ubiquitin-proteasome system and the role of its inhibitors in cancer therapy. Open Biol. 2021;11(4):200390. doi:10.1098/rsob.200390
   PubMed Web of Science ®Google Scholar
• Chen D, Frezza M, Schmitt S, et al. Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives. Curr Cancer Drug Targets. 2011;11(3):239–253. doi:10.2174/156800911794519752
   PubMed Web of Science ®Google Scholar
• Arkwright R, Pham TM, Zonder JA, et al. The preclinical discovery and development of bortezomib for the treatment of mantle cell lymphoma. Expert Opin Drug Discov. 2017;12(2):225–235. doi:10.1080/17460441.2017.1268596
   PubMed Web of Science ®Google Scholar
• Qing W, Xing X, Feng D, et al. Indocyanine green loaded pH-responsive bortezomib supramolecular hydrogel for synergistic chemo-photothermal/photodynamic colorectal cancer therapy. Photodiagnosis Photodyn Ther. 2021;36:102521. doi:10.1016/j.pdpdt.2021.102521
   PubMed Web of Science ®Google Scholar
• Tsumagari K, Abd Elmageed ZY, Sholl AB, et al. Bortezomib sensitizes thyroid cancer to BRAF inhibitor in vitro and in vivo. Endocr Relat Cancer. 2018;25(1):99–109. doi:10.1530/ERC-17-0182
   PubMed Web of Science ®Google Scholar
• Wu P, Oren O, Gertz MA, et al. Proteasome Inhibitor-Related Cardiotoxicity: mechanisms, Diagnosis, and Management. Curr Oncol Rep. 2020;22(7):66. doi:10.1007/s11912-020-00931-w
   PubMed Web of Science ®Google Scholar
• Yamamoto S, Egashira N. Pathological Mechanisms of Bortezomib-Induced Peripheral Neuropathy. Int J Mol Sci. 2021;22(2):888. doi:10.3390/ijms22020888
   PubMed Web of Science ®Google Scholar
• Blum A, Wang P, Zenklusen JC. SnapShot: TCGA-Analyzed Tumors. Cell. 2018;173(2):530. doi:10.1016/j.cell.2018.03.059
   PubMed Web of Science ®Google Scholar
• Falkenberg KJ, Newbold A, Gould CM, et al. A genome scale RNAi screen identifies GLI1 as a novel gene regulating vorinostat sensitivity. Cell Death Differ. 2016;23(7):1209–1218. doi:10.1038/cdd.2015.175
   PubMed Web of Science ®Google Scholar
• Meng Y, Zhao Q, An L, et al. A TNFR2-hnRNPK Axis Promotes Primary Liver Cancer Development via Activation of YAP Signaling in Hepatic Progenitor Cells. Cancer Res. 2021;81(11):3036–3050. doi:10.1158/0008-5472.CAN-20-3175
   PubMed Web of Science ®Google Scholar
• Wilkerson MD, Hayes DN. ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking. Bioinformatics. 2010;26(12):1572–1573. doi:10.1093/bioinformatics/btq170
   PubMed Web of Science ®Google Scholar
• Ritchie ME, Phipson B, Wu D, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43(7):e47. doi:10.1093/nar/gkv007
   PubMed Web of Science ®Google Scholar
• Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102(43):15545–15550. doi:10.1073/pnas.0506580102
   PubMed Web of Science ®Google Scholar
• Yu G, Wang L-G, Han Y, et al. clusterProfiler: an R package for comparing biological themes among gene clusters. Omics. 2012;16(5):284–287. doi:10.1089/omi.2011.0118
   PubMed Web of Science ®Google Scholar
• Collaborators. Gene Ontology Consortium: going forward. Nucleic Acids Res. 2015;43(D1):D1049–56. doi:10.1093/nar/gku1179
   PubMed Web of Science ®Google Scholar
• Kanehisa M, Goto S. KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 2000;28(1):27–30. doi:10.1093/nar/28.1.27
   PubMed Web of Science ®Google Scholar
• Song WM, Zhang B. Multiscale Embedded Gene Co-expression Network Analysis. PLoS Comput Biol. 2015;11(11):e1004574. doi:10.1371/journal.pcbi.1004574
   PubMed Web of Science ®Google Scholar
• Wang S, Su W, Zhong C, et al. An Eight-CircRNA Assessment Model for Predicting Biochemical Recurrence in Prostate Cancer. Front Cell Dev Biol. 2020;8:599494. doi:10.3389/fcell.2020.599494
   PubMed Web of Science ®Google Scholar
• Li T, Fan J, Wang B, et al. TIMER: a Web Server for Comprehensive Analysis of Tumor-Infiltrating Immune Cells. Cancer Res. 2017;77(21):e108–e110. doi:10.1158/0008-5472.CAN-17-0307
   PubMed Web of Science ®Google Scholar
• Chen B, et al. Profiling Tumor Infiltrating Immune Cells with CIBERSORT. Methods Mol Biol. 2018;1711:243–259.
   PubMedGoogle Scholar
• Zhu K, Xiaoqiang L, Deng W, et al. Development and validation of a novel lipid metabolism-related gene prognostic signature and candidate drugs for patients with bladder cancer. Lipids Health Dis. 2021;20(1):146. doi:10.1186/s12944-021-01554-1
   PubMed Web of Science ®Google Scholar
• Plattner C, Finotello F, Rieder D. Deconvoluting tumor-infiltrating immune cells from RNA-seq data using quanTIseq. Methods Enzymol. 2020;636:261–285.
   PubMed Web of Science ®Google Scholar
• Lu H, Wu J, Liang L, et al. Identifying a Novel Defined Pyroptosis-Associated Long Noncoding RNA Signature Contributes to Predicting Prognosis and Tumor Microenvironment of Bladder Cancer. Front Immunol. 2022;13:803355. doi:10.3389/fimmu.2022.803355
   PubMed Web of Science ®Google Scholar
• Aran D, Hu Z, Butte AJ. xCell: digitally portraying the tissue cellular heterogeneity landscape. Genome Biol. 2017;18(1):220. doi:10.1186/s13059-017-1349-1
   PubMed Web of Science ®Google Scholar
• Yang Z, Wei X, Pan Y, et al. A new risk factor indicator for papillary thyroid cancer based on immune infiltration. Cell Death Dis. 2021;12(1):51. doi:10.1038/s41419-020-03294-z
   PubMed Web of Science ®Google Scholar
• Collins GA, Goldberg AL. The Logic of the 26S Proteasome. Cell. 2017;169(5):792–806. doi:10.1016/j.cell.2017.04.023
   PubMed Web of Science ®Google Scholar
• Xie Y. Structure, assembly and homeostatic regulation of the 26S proteasome. J Mol Cell Biol. 2010;2(6):308–317. doi:10.1093/jmcb/mjq030
   PubMed Web of Science ®Google Scholar
• Rousseau A, Bertolotti A. Regulation of proteasome assembly and activity in health and disease. Nat Rev Mol Cell Biol. 2018;19(11):697–712. doi:10.1038/s41580-018-0040-z
   PubMed Web of Science ®Google Scholar
• Xie Y. Feedback regulation of proteasome gene expression and its implications in cancer therapy. Cancer Metastasis Rev. 2010;29(4):687–693. doi:10.1007/s10555-010-9255-y
   PubMed Web of Science ®Google Scholar
• Chen L, Brewer MD, Guo L, et al. Enhanced Degradation of Misfolded Proteins Promotes Tumorigenesis. Cell Rep. 2017;18(13):3143–3154. doi:10.1016/j.celrep.2017.03.010
   PubMed Web of Science ®Google Scholar
• Jan M, Sperling AS, Ebert BL. Cancer therapies based on targeted protein degradation - lessons learned with lenalidomide. Nat Rev Clin Oncol. 2021;18(7):401–417. doi:10.1038/s41571-021-00479-z
   PubMed Web of Science ®Google Scholar
• Aubrey BJ, Strasser A, Kelly GL. Tumor-Suppressor Functions of the TP53 Pathway. Cold Spring Harb Perspect Med. 2016;6:5. doi:10.1101/cshperspect.a026062
   Web of Science ®Google Scholar
• Olivier M, Hollstein M, Hainaut P. TP53 mutations in human cancers: origins, consequences, and clinical use. Cold Spring Harb Perspect Biol. 2010;2(1):a001008. doi:10.1101/cshperspect.a001008
   PubMed Web of Science ®Google Scholar
• Li Z, Pearlman AH, Hsieh P. DNA mismatch repair and the DNA damage response. DNA Repair (Amst). 2016;38:94–101. doi:10.1016/j.dnarep.2015.11.019
   PubMed Web of Science ®Google Scholar
• Zhang Y, Tseng JT, Lien IC, et al. mRNAsi Index: machine Learning in Mining Lung Adenocarcinoma Stem Cell Biomarkers. Genes. 2020;11(3):257.
   PubMed Web of Science ®Google Scholar
• Najafi M, Mortezaee K, Majidpoor J. Cancer stem cell (CSC) resistance drivers. Life Sci. 2019;234:116781. doi:10.1016/j.lfs.2019.116781
   PubMed Web of Science ®Google Scholar
• Kapetanou M, Chondrogianni N, Petrakis S, et al. Proteasome activation enhances stemness and lifespan of human mesenchymal stem cells. Free Radic Biol Med. 2017;103:226–235. doi:10.1016/j.freeradbiomed.2016.12.035
   PubMed Web of Science ®Google Scholar
• Vilchez D, Boyer L, Morantte I, et al. Increased proteasome activity in human embryonic stem cells is regulated by PSMD11. Nature. 2012;489(7415):304–308. doi:10.1038/nature11468
   PubMed Web of Science ®Google Scholar
• Yang Y, Cao L, Guo Z, et al. Deubiquitinase UCHL5 stabilizes ELK3 to potentiate cancer stemness and tumor progression in pancreatic adenocarcinoma (PAAD). Exp Cell Res. 2022;421(2):113402. doi:10.1016/j.yexcr.2022.113402
   PubMed Web of Science ®Google Scholar
• Giannelli G, Koudelkova P, Dituri F, et al. Role of epithelial to mesenchymal transition in hepatocellular carcinoma. J Hepatol. 2016;65(4):798–808. doi:10.1016/j.jhep.2016.05.007
   PubMed Web of Science ®Google Scholar
• He S, Cao R, Mao Y, et al. Alternative splicing of PSMD13 mediated by genetic variants is significantly associated with endometrial cancer risk. J Gynecol Oncol. 2023;34. doi:10.3802/jgo.2023.34.e40
   Web of Science ®Google Scholar
• Xuan DTM, Wu -C-C, Kao T-J, et al. Prognostic and immune infiltration signatures of proteasome 26S subunit, non-ATPase (PSMD) family genes in breast cancer patients. Aging. 2021;13(22):24882–24913. doi:10.18632/aging.203722
   PubMedGoogle Scholar
• Salah Fararjeh A, Al-Khader A, Al-Saleem M, et al. The Prognostic Significance of Proteasome 26S Subunit, Non-ATPase (PSMD) Genes for Bladder Urothelial Carcinoma Patients. Cancer Inform. 2021;20:11769351211067692. doi:10.1177/11769351211067692
   Web of Science ®Google Scholar
• Zhu X, Li S, Xu B, et al. Cancer evolution: a means by which tumors evade treatment. Biomed Pharmacother. 2021;133:111016. doi:10.1016/j.biopha.2020.111016
   PubMedGoogle Scholar
• Ligorio M, Sil S, Malagon-Lopez J, et al. Stromal Microenvironment Shapes the Intratumoral Architecture of Pancreatic Cancer. Cell. 2019;178(1):160–175.e27. doi:10.1016/j.cell.2019.05.012
   PubMed Web of Science ®Google Scholar
• Kaushik N, Kim S, Suh Y, et al. Proinvasive extracellular matrix remodeling for tumor progression. Arch Pharm Res. 2019;42(1):40–47. doi:10.1007/s12272-018-1097-0
   PubMed Web of Science ®Google Scholar
• de Miranda MC, Melo MIAD, Cunha PDS, et al. Roles of mesenchymal stromal cells in the head and neck cancer microenvironment. Biomed Pharmacother. 2021;144:112269. doi:10.1016/j.biopha.2021.112269
   PubMed Web of Science ®Google Scholar
• Nilendu P, Sarode SC, Jahagirdar D, et al. Mutual concessions and compromises between stromal cells and cancer cells: driving tumor development and drug resistance. Cell Oncol. 2018;41(4):353–367. doi:10.1007/s13402-018-0388-2
   PubMed Web of Science ®Google Scholar
• Atiya H, et al. Mesenchymal Stem Cells in the Tumor Microenvironment. Adv Exp Med Biol. 2020;1234:31–42.
   PubMed Web of Science ®Google Scholar
• Chen DS, Mellman I. Elements of cancer immunity and the cancer-immune set point. Nature. 2017;541(7637):321–330. doi:10.1038/nature21349
   PubMed Web of Science ®Google Scholar
• Dzobo K, Senthebane DA, Dandara C. The Tumor Microenvironment in Tumorigenesis and Therapy Resistance Revisited. Cancers. 2023;15(2). doi:10.3390/cancers15020376
   PubMed Web of Science ®Google Scholar